| abstract |
1. The polypeptide containing the analogue of the protein of complement factor B, where the analog of complement factor B contains a mutation of a free cysteine amino acid. The polypeptide according to claim 1, where the mutation contains a replacement for free cysteine. The polypeptide according to claim 2, wherein the free cysteine is replaced by more than one amino acid. The polypeptide according to claim 1, wherein the complement factor protein analogue B is an analogue of SEQ ID NO: 4, and the complement factor protein protein B has cysteine amino acids forming disulfide bonds and a free cysteine amino acid is replaced with another amino acid. The polypeptide according to claim 2, wherein the free cysteine is replaced by an amino acid selected from the group consisting of alanine, histidine, isoleucine, leucine, methionine, phenylalanine, serine, threonine, tyrosine and valine. The polypeptide according to claim 1, where the mutation contains a deletion of free cysteine. The polypeptide of claim 1, wherein the complement factor B protein analogue is a human complement complement factor protein protein analogue. The polypeptide according to claim 1, where free cysteine corresponds to amino acid 292 of SEQ ID NO: 1.9. The polypeptide of claim 1, wherein the complement factor B protein analogue contains mutations corresponding to K258A, R259A, K260A, D279G and N285D from SEQ ID NO: 1.10. The polypeptide according to claim 1, where the analogue of the protein of complement factor B contains amino acids 26-480 of SEQ ID NO: 2.11. The polypeptide according to claim 1, where the analogue of the protein of complement factor B does not contain amino acids 481-764 of SEQ ID NO: 2.12. The polypeptide of claim 1, wherein said complement factor B protein analogue has an increased C3b binding affinity compared to the corresponding natural complement factor B protein and said complement factor B protein analogue (i) has a reduced protease� |